New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I Formula I.1 Formula I.2 Formula IA Formula IB Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine doxorubicin daunorubicin cyclophosphamide busulfex busulfan vinblastine vincristine bleomycin e...

Disclosed are methods of treating a tumor in a subject that include a step of administering to the subject a therapeutic composition that comprises: (a) mycophenolic acid an analogue thereof or a derivative thereof; and (b) at least one antineoplastic agent. The antineoplastic agent may include at least one of 5-fluouracil (5-FU) paclitaxel oxaliplatin doxorubicin etoposide irinotecan bleomycin imiquimod 13-cis-retinoic acid and combinations thereof. The mycophenolic acid may not be derivatized....

Antitumour combinations of VEGF inhibitors with Irinotecan of therapeutic use in the treatment of neoplastic diseases.

Un ensayo para determinar si un paciente es un respondedor a tratamiento con irinotecan que comprendemedios para determinar el nivel de expresión en una célula tumoral o tejido tumoral de cada una de las proteínascodificadas por los genes seleccionados del grupo que consiste en: ERBB2 que codifica la secuencia deaminoácidos de SEQ ID Nº 23 GRB7 que codifica la secuencia de aminoácidos de SEQ ID Nº 24 quinasa JNK1que codifica la secuencia de aminoácidos de SEQ ID Nº 26 BCL2 que codifica la secuen...

The present invention relates to the use of copper ions to achieve enhanced retention of a therapeutic agent within a liposome. The invention may be employed to more effectively deliver a liposomally encapsulated therapeutic agent to a target site in vitro and in vivo for anti-cancer or other therapy. The liposome may comprise an interior buffer solution containing the therapeutic agent, the solution having a pH less than 6.5 and most preferably approximating pH 3.5. At least some of the copper ...

New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I Formula I.1 Formula I.2 Formula IA Formula IB Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine doxorubicin daunorubicin cyclophosphamide busulfex busulfan vinblastine vincristine bleomycin e...